乙型肝炎病毒相关性肝癌抗病毒治疗的现状

Antiviral therapy for hepatitis B virus-associated hepatocellular carcinoma

乙型肝炎病毒感染是我国原发性肝癌的主要病因,高病毒载量是肝癌发生、发展及预后的重要影响因素.外科治疗、局部治疗、放射治疗、系统治疗等均有激活乙肝病毒的潜在可能性,影响抗肿瘤治疗的实施和效果.抗病毒治疗是乙型肝炎病毒相关性肝癌的最基本的病因治疗,在上述治疗的基础上联合抗病毒治疗可有效降低病毒载量、肿瘤复发与转移率,延长患者生存时间,提高患者生存质量,具有较好的临床效果.

Hepatitis B virus （HBV） is the main cause of hepatocellular carcinoma （HCC） in China. High HBV load is an important factor affecting the development and prognosis of primary HCC. Since surgery, local therapy and other treatmnents have the potential to reactivate HBV, antiviral therapy is considered the most fundamental treatment for HCC. Combination therapy with above treatment and antiviral therapy can significantly reduce the copies of HBV DNA, decrease tumor recurrence and metastasis, and extend survival time in patients with middle or advanced stage HCC.